Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CZ1S for Injection local infiltration for postoperative analgesia after inguinal hernia repair (Phase II)
CTR20252265Phase 2Active
- Sponsor
- Zhejiang Cuize Pharmaceutical Technology
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CZ1S in postoperative pain (2 arms), sponsored by Zhejiang Cuize Pharmaceutical Technology. Primary endpoint: Area under the curve of movement-evoked pain intensity scores within 72 hours after dosing. Started Aug 2025; status: active.
02
Drugs
CZ1S
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20252265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252265.